What the Company Does

LabGenius specialises in the discovery and optimisation of novel antibody therapeutics using a proprietary platform that integrates robotics, automation, and artificial intelligence. Rather than relying purely on human intuition and manual laboratory work, the company has built an end-to-end system where machine learning models guide the design of experiments, and automated laboratory infrastructure carries them out. The results of these experiments then feed back into the models, creating a continuous learning loop that improves with each iteration.

The company focuses particularly on multispecific antibodies, which are complex molecules engineered to bind to more than one target simultaneously. These molecules hold significant therapeutic promise, especially in areas such as oncology and immunology, but they are notoriously difficult to design because of the enormous number of possible molecular configurations. LabGenius uses its technology to explore this complexity systematically and efficiently.

At the heart of the company's operations is the idea of a self-driving lab, where the process of hypothesis generation, experimentation, and analysis is largely automated. This approach is intended to dramatically accelerate the pace of discovery while reducing the cost and human bias inherent in traditional research pipelines.

The EVA Platform

LabGenius's flagship technology is known as EVA, which stands for its evolutionary and machine-learning-driven discovery engine. EVA represents the integration of three key components: machine learning models, robotic automation, and high-throughput biological assays.

The platform works by having its algorithms propose a set of candidate molecules based on a defined therapeutic objective. These candidates are then physically created and tested in the company's automated laboratories. The experimental data generated is fed back into the machine learning models, which learn from both successful and unsuccessful outcomes. Over successive cycles, the system converges on molecules with the desired properties, such as high potency, selectivity, and favourable developability characteristics.

This closed-loop design distinguishes LabGenius from companies that rely solely on computational prediction. By grounding its algorithms in real experimental data generated at scale, the company aims to produce more reliable and translatable results.

Products and Services

LabGenius primarily offers its capabilities through its drug discovery platform and partnerships rather than as off-the-shelf products. The main offerings include the following:

Antibody discovery and optimisation. The company designs and engineers novel antibody therapeutics, including complex multispecific formats, tailored to specific disease targets and therapeutic goals.

Machine-learning-guided molecular design. LabGenius applies its proprietary algorithms to intelligently explore protein sequence and structure space, identifying candidate molecules with optimised functional profiles.

Automated high-throughput experimentation. Through its robotic laboratory infrastructure, the company can generate and test large numbers of molecular variants rapidly, producing the high-quality datasets that power its learning systems.

Developability optimisation. Beyond identifying molecules that simply bind to their targets, LabGenius works to ensure that candidates possess the properties needed to become viable drugs, including stability, manufacturability, and low immunogenicity.

Strategic partnerships and collaborations. The company works with pharmaceutical and biotechnology partners to apply its platform to specific therapeutic programmes, combining LabGenius's discovery technology with partners' disease expertise and clinical development capabilities.

Therapeutic Focus

While the platform is broadly applicable to protein engineering challenges, LabGenius has directed significant attention toward oncology and immune-related diseases. Multispecific antibodies are particularly valuable in cancer treatment, where engaging multiple biological targets at once can improve efficacy and selectivity, potentially reducing side effects associated with less precise therapies. The company's technology is designed to tackle the design challenges that make these advanced molecules so difficult to develop through conventional means.

Technology and Innovation

The company's competitive advantage lies in the tight integration of its computational and experimental systems. Many organisations pursue either computational drug design or laboratory automation, but LabGenius has built its business around the fusion of the two. This integration allows the company to run active learning experiments, where the machine learning system actively decides which experiments will be most informative to conduct next, rather than testing molecules at random or according to fixed rules.

This active learning approach means that each experimental cycle is designed to maximise the information gained, allowing the platform to learn efficiently even in the enormous and complex landscape of possible protein designs. The result is a discovery process that becomes progressively smarter and more targeted over time.

People and Culture

Founded by Dr. James Field, who holds a background in synthetic biology, LabGenius has assembled a multidisciplinary team that brings together expertise in molecular biology, protein engineering, machine learning, software engineering, and laboratory automation. This blend of disciplines reflects the company's fundamentally hybrid nature, sitting between the worlds of computer science and life sciences.

The organisation cultivates a research-driven and innovation-focused culture, attracting talent interested in applying cutting-edge computational methods to solve some of the most challenging problems in biology and medicine.

Funding and Growth

LabGenius has attracted investment from venture capital firms and strategic investors interested in the convergence of artificial intelligence and drug discovery. This funding has supported the expansion of its laboratory infrastructure, the growth of its team, and the advancement of its discovery platform. The company's progress reflects broader industry interest in AI-enabled biotechnology, an area that has seen substantial investment and attention as pharmaceutical companies seek to improve the efficiency and success rates of drug development.

Position in the Industry

LabGenius is part of a growing cohort of companies applying machine learning to therapeutic discovery, but it distinguishes itself through its emphasis on combining computation with large-scale, automated wet-lab experimentation. In an industry where the cost and failure rate of drug development remain very high, the company's data-driven and automated approach offers a compelling proposition: the potential to discover better molecules faster and more reliably than traditional methods allow.

By focusing on some of the most technically demanding molecule formats, such as multispecific antibodies, LabGenius is targeting areas of high unmet need and significant commercial value. Its work contributes to the broader transformation of drug discovery from a largely manual, intuition-driven craft into a more systematic, engineering-led discipline.

Summary

LabGenius Limited is a UK-based biotechnology company that leverages machine learning, robotic automation, and high-throughput biology to discover and optimise next-generation antibody therapeutics. Through its EVA platform and its closed-loop, active learning approach, the company seeks to intelligently explore the vast landscape of possible protein molecules and identify superior drug candidates, with a particular focus on complex multispecific antibodies for oncology and immune-related conditions. Combining the disciplines of artificial intelligence and molecular biology, LabGenius represents an example of the modern, technology-driven evolution of pharmaceutical research and development.